Dyno Therapeutics Collaborates with Roche to Develop AAV Gene Therapy Vectors for Neurological Diseases
Shots:
- Dyno has partnered with Roche to advance next-gen AAV vectors for neurological gene therapies, expanding on their 2020 partnership on neurological and liver-directed therapies. Roche will get access to Dyno’s field-leading platform and sequence design tech for in vivo gene delivery
- agreement, Dyno will design and discover novel AAV capsids with enhanced properties, while Roche will handle capsid validation, preclinical, clinical, and commercialization activities for neurological gene therapy candidates using Dyno’s capsids
- Dyno is entitled to receive an upfront of $50M, other payments during the research phase as well as potential preclinical, clinical & sales milestones of over $1B plus net-sales-based royalties
Ref: Dyno Therapeutics | Image: Dyno Therapeutics & Roche
Related News:- Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
